Journal article
Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.
Abstract
Abstract
Introduction. The NCIC CTG is conducting phase II testing to establish the tolerability and estimate the efficacy of combining lenalidomide (L) + melphalan (M) over multiple cycles for previously untreated patients with multiple myeloma who are ineligible for stem cell transplantation. We report the data from the preliminary safety phase of this trial.
Authors
White DJ; Kovacs MJ; Belch A; Stewart K; Chen C; Rubin S; Macdonald DA; Harnett E; Chapman J-AW; Shepherd LE
Journal
Blood, Vol. 110, No. 11,
Publisher
American Society of Hematology
Publication Date
November 16, 2007
DOI
10.1182/blood.v110.11.189.189
ISSN
0006-4971